

Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia

NCT06833593

Status RECRUITING
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment 510 participants

Key Eligibility Criteria

Inclusion (4)

- Adult (≥18 years)
- Monomicrobial EF-BSI
- Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy
- Written informed consent

Exclusion (2)

- Short term (within 3 days from BSI) mortality
- Other concomitant infection

Locations (4 total)

Ospedale Maggiore "Carlo Alberto Pizzardi" di Bologna, Bologna, Bologna, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Bologna, Italy
Azienda Ospedaliero Universitaria di Catanzaro "Mater Domini", Catanzaro, Catanzaro, Italy
... and 1 more locations